Trials / Completed
CompletedNCT01024231
Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma
A Phase 1b, Open-label, Multicenter, Multidose, Dose-escalation Study of BMS-936558 (MDX-1106) in Combination With Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 127 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the safety and tolerability of treatment with BMS-936558 (MDX-1106) in combination with Ipilimumab (BMS-734016) when given at the same time or as a sequenced regimen in subjects with unresectable Stage III or Stage IV malignant melanoma (MEL)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-936558 (MDX1106-04) | |
| DRUG | Ipilimumab |
Timeline
- Start date
- 2009-12-14
- Primary completion
- 2014-02-04
- Completion
- 2019-04-01
- First posted
- 2009-12-02
- Last updated
- 2021-03-22
- Results posted
- 2021-03-22
Locations
4 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT01024231. Inclusion in this directory is not an endorsement.